Education
About Us
Working with TipRanks
Follow Us
Irhythm Technologies (IRTC)
NASDAQ:IRTC
Earnings Data
Report Date
Jul 31, 2025TBA Not Confirmed
Period Ending
2025 (Q2)Consensus EPS Forecast
-0.53Last Year’s EPS
-0.65Same Quarter Last Year
Strong Buy
Based on 8 Analysts Ratings
Earnings Call Summary
Earnings Call Date:May 01, 2025
|% Change Since: 33.74%
|Next Earnings Date:Jul 31, 2025
Earnings Call Sentiment|Positive
The earnings call reflects a strong performance with significant revenue growth and successful international expansion, notably with Zio AT's success. However, challenges with reimbursement in Japan, ongoing FDA remediation, and tariff concerns pose notable risks.Company Guidance
During the iRhythm Technologies, Inc. first quarter 2025 earnings call, guidance was provided indicating a strong start to the year with revenue reaching $158.7 million, reflecting over 20% growth compared to the first quarter of 2024. The company updated its full-year 2025 revenue guidance to $690 million to $700 million and adjusted EBITDA margin expectations to between 7.5% and 8.5%. This guidance reflects increased demand, particularly from the Zio AT product line, which now represents 14% of revenue, and a growing contribution from innovative channel partners in undiagnosed arrhythmia monitoring. The company remains focused on expanding its presence in primary care channels, which now account for nearly one-third of monitoring volumes, and progressing international opportunities, including recent launches in Japan. iRhythm also highlighted improvements in adjusted EBITDA margin, which improved by 750 basis points to negative 1.7% of revenue, driven by operational efficiencies and volume leverage.Strong Revenue Growth
iRhythm achieved robust top line results of $158.7 million, representing over 20% growth compared to the first quarter of 2024.
Record New Account Onboarding
The company observed significant volume demand throughout Q1 2025, continuing from record new account onboarding in 2024.
10 Million Cumulative Patient Reports
iRhythm has surpassed 10 million cumulative patient reports since its inception, marking a significant milestone in its history.
Strong Performance in Zio AT
Zio AT demand continued strongly, contributing significantly to revenue, with Zio AT's revenue growth rate significantly outpacing the overall corporate average.
Successful International Expansion
iRhythm's international business saw progress, including a commercial launch in Japan and record volume in the UK, despite ongoing reimbursement challenges.
IRTC Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
IRTC Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 01, 2025 | $108.59 | $131.12 | +20.75% |
Feb 20, 2025 | $112.67 | $119.44 | +6.01% |
Oct 30, 2024 | $75.77 | $72.44 | -4.39% |
Aug 01, 2024 | $84.22 | $73.88 | -12.28% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Irhythm Technologies (IRTC) report earnings?
Irhythm Technologies (IRTC) is schdueled to report earning on Jul 31, 2025, TBA Not Confirmed.
What is Irhythm Technologies (IRTC) earnings time?
Irhythm Technologies (IRTC) earnings time is at Jul 31, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is IRTC EPS forecast?
IRTC EPS forecast for the fiscal quarter 2025 (Q2) is -0.53.